COVID-19疫苗接种对心肺的影响:全面叙述审查
Lauren T Forchette1, Luis Palma1, Christian Sanchez2
1Florida State University Internal Medicine Residency at Sarasota Memorial Hospital, Sarasota, FL 34239, USA.
Vaccines
|June 27, 2025
概括
COVID-19 mRNA疫苗可能会导致罕见的心肺副作用,但接种疫苗的好处超过了风险. 自然感染构成了比疫苗相关并发症更大的威胁.
科学领域:
- 免疫学 免疫学 免疫学
- 心脏病学 心脏病学
- 肺部病理学 肺部病理学
背景情况:
- COVID-19 mRNA疫苗的广泛使用引发了人们对潜在副作用的担忧.
- 在接种疫苗后报告有心肺复杂症.
研究的目的:
- 综合审查COVID-19mRNA疫苗所产生的心肺影响的证据.
- 讨论这些事件的临床过程,诊断,管理和病理生理学.
主要方法:
- 对现有文献进行系统审查.
- 报告心肺不良事件的证据综合.
- 对临床结果和拟议机制的分析.
主要成果:
- 确定的心血管并发症:心肌炎,心周炎,心律失常等.
- 确定的肺部并发症:肺栓塞,肺炎和其他.
- 与自然感染相比,接种疫苗的好处大大超过了风险.
结论:
- 虽然COVID-19 mRNA疫苗与某些心肺副作用有关,但这些通常是罕见的.
- 疫苗相关并发症的预后明显好于自然COVID-19感染引起的并发症.
- 风险与益处的概况强烈支持COVID-19疫苗接种.
更多相关视频
相关概念视频
01:25Cardiopulmonary Resuscitation IV: Pharmacological Management
81
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
81
01:20COPD: Pathogenesis and Clinical Features
535
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
535
01:29Pneumonia II: Pathophysiology
603
The pathophysiology of pneumonia involves the following steps:
603
01:26COPD: Management Using Bronchodilators and Corticosteroids
324
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
324
01:30Pneumonia III: Complications and Assessment
453
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
453
01:29Pulmonary Embolism I: Introduction
50
Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
50